Anti-COVID-19 dimeric antigen receptor T (DAR-T) cell therapy is being developed by Sorrento Therapeutics for the treatment of COVID-2019 infection. The cell therapy is based on the company's proprietary non-viral vector Knock out/knock in (KOKI) technology and is derived from the G-MAB antibody library. Preclinical development is underway in the US.
Sorrento Therapeutics believes that the KOKI DAR-T technology offers a number of advantages over virus based technology's including site-specific integration, enhanced clonal expansion and a streamlined transgene construct production. By using healthy donor T cells, the technology avoids reliance on the patient’s T cells, thus avoiding treatment delays and supporting reduced manufacturing costs ultimately overcoming some drawbacks of the CAR-T therapy. In DAR-T therapy, Sorrento Therapeutics has incorporated fab fragments in the construct, instead of ScFV.
In March 2020, Sorrento Therapeutics entered into a research testing agreement with the University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates. 
Key Development Milestones
Preclinical development is underway in the US  .
Sorrento Therapeutics has filed a patent application no. WO 2019 173 837A1 covering ‘Dimeric antigen receptors (DAR)’  .